Kezar Life Sciences (KZR) Invested Capital (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Invested Capital for 5 consecutive years, with $70.1 million as the latest value for Q4 2025.
- For Q4 2025, Invested Capital fell 42.63% year-over-year to $70.1 million; the TTM value through Dec 2025 reached $70.1 million, down 42.63%, while the annual FY2025 figure was $70.1 million, 42.63% down from the prior year.
- Invested Capital hit $70.1 million in Q4 2025 for Kezar Life Sciences, down from $88.3 million in the prior quarter.
- Across five years, Invested Capital topped out at $307.4 million in Q2 2022 and bottomed at $70.1 million in Q4 2025.
- Average Invested Capital over 5 years is $179.8 million, with a median of $161.9 million recorded in 2024.
- Year-over-year, Invested Capital soared 145.38% in 2022 and then plummeted 42.63% in 2025.
- Kezar Life Sciences' Invested Capital stood at $206.9 million in 2021, then skyrocketed by 35.28% to $279.9 million in 2022, then fell by 29.41% to $197.6 million in 2023, then plummeted by 38.18% to $122.1 million in 2024, then tumbled by 42.63% to $70.1 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $70.1 million, $88.3 million, and $97.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.